Determining that required criteria are met… Deployment begins earlier this year
The World Health Organization (WHO) has listed Pfizer and Bioentech’s COVID-19 vaccine on the Emergency Use List (EUL).
According to a report by Reuters, the World Health Organization, the United Nations (UN) health-specialized organization, announced that on December 31 (local time), as part of an effort to speed up access to the COVID-19 vaccine by developing countries, Pfizer and Bioentech. It was decided to put the vaccine on the list for emergency use.
The first Corona 19 vaccine added to the emergency use list is a vaccine from Pfizer and BioEntech.
WHO plans to work with local partners to inform national health authorities about the vaccines given twice and the expected vaccine benefits.
The Emergency Use List was created to help low-income countries without self-regulatory resources quickly approve drugs for new diseases such as COVID-19.
The WHO reviewed through expert meetings and concluded that Pfizer and Bioentech’s messenger RNA (mRNA) vaccines met essential criteria for safety and efficacy, and that the benefits offered by the vaccine offset the potential risks.
“This is a very positive step in ensuring global access to the COVID-19 vaccine,” said Mariangela Shimao, Deputy Secretary General of the WHO’s Drug Access Program. “However, we have provided sufficient vaccine supplies to meet the needs of priority populations around the world. “I want to emphasize the need for more global efforts to achieve it.”
The UN Health Organization is working with the World Vaccine Alliance (GAVI) and the Infectious Disease Prevention and Innovation Alliance (CEPI) to secure and distribute vaccines for countries around the world, including developing countries, the COVAX facility. ).
COVAX has signed a contract for about 2 billion doses of the Corona 19 vaccine so far, and is expected to start its first distribution earlier this year. In addition, discussions are ongoing to secure additional vaccines from Pfizer and Bioentech.
However, despite these efforts, Pfizer and Bioentech’s vaccines are likely to be difficult to distribute, especially in developing countries without adequate infrastructure, as they must comply with strict storage and transportation requirements, such as keeping below -70 degrees Celsius.
Currently, Pfizer and Bioentech’s vaccines are approved for emergency use in the UK, Europe, the US, Canada, Bahrain, Israel, Kuwait, Mexico, Oman, Qatar, Saudi Arabia and Singapore. In clinical trials, Pfizer and Bioentech’s vaccine showed a 95% COVID-19 prevention rate when administered twice every 21 days.
Copyright © Medical News Unauthorized reproduction and redistribution prohibited